NeoGenomics, Inc. (NASDAQ:NEO) Given Consensus Rating of "Moderate Buy" by Brokerages

NeoGenomics, Inc. (NASDAQ:NEO - Get Free Report) has been given an average rating of "Moderate Buy" by the ten ratings firms that are covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $19.60.

Several equities analysts recently commented on the company. The Goldman Sachs Group reduced their price target on NeoGenomics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Piper Sandler reduced their price target on NeoGenomics from $21.00 to $18.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Benchmark lowered NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Needham & Company LLC cut their target price on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research report on Wednesday, February 19th. Finally, Jefferies Financial Group assumed coverage on NeoGenomics in a research report on Tuesday, December 10th. They issued a "buy" rating and a $22.00 target price on the stock.

NeoGenomics Stock Performance

NASDAQ NEO opened at $10.10 on Monday. The business's 50-day simple moving average is $13.79 and its 200-day simple moving average is $15.01. The firm has a market capitalization of $1.30 billion, a P/E ratio of -16.29 and a beta of 1.28. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.98 and a quick ratio of 1.91. NeoGenomics has a 1-year low of $8.98 and a 1-year high of $19.11.

Remove Ads

NeoGenomics (NASDAQ:NEO - Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). The company had revenue of $172.00 million for the quarter, compared to analyst estimates of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. Equities analysts predict that NeoGenomics will post -0.2 EPS for the current year.

Institutional Investors Weigh In On NeoGenomics

A number of institutional investors have recently made changes to their positions in NEO. SBI Securities Co. Ltd. bought a new stake in shares of NeoGenomics in the 4th quarter valued at approximately $26,000. Versant Capital Management Inc increased its holdings in shares of NeoGenomics by 174.9% in the 4th quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock valued at $30,000 after acquiring an additional 1,142 shares during the last quarter. Quarry LP bought a new position in NeoGenomics during the 3rd quarter worth $40,000. Sterling Capital Management LLC grew its stake in NeoGenomics by 788.7% during the 4th quarter. Sterling Capital Management LLC now owns 3,706 shares of the medical research company's stock worth $61,000 after buying an additional 3,289 shares during the last quarter. Finally, KBC Group NV grew its stake in NeoGenomics by 33.1% during the 3rd quarter. KBC Group NV now owns 4,530 shares of the medical research company's stock worth $67,000 after buying an additional 1,127 shares during the last quarter. 98.50% of the stock is currently owned by institutional investors.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.